• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Novavax downgraded by TD Cowen with a new price target

    4/20/23 7:44:37 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email
    TD Cowen downgraded Novavax from Outperform to Market Perform and set a new price target of $10.00 from $55.00 previously
    Get the next $NVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    6/17/2025$6.00Sell
    Citigroup
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    8/9/2023$15.00Neutral → Buy
    B. Riley Securities
    4/20/2023$55.00 → $10.00Outperform → Market Perform
    TD Cowen
    3/1/2023$29.00 → $10.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcglynn Margaret G converted options into 10,420 shares, increasing direct ownership by 69% to 25,588 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      6/16/25 4:10:45 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Alton Gregg H converted options into 10,420 shares, increasing direct ownership by 57% to 28,805 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      6/16/25 4:09:43 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director King Rachel K. converted options into 10,420 shares, increasing direct ownership by 71% to 25,190 units (SEC Form 4)

      4 - NOVAVAX INC (0001000694) (Issuer)

      6/13/25 9:41:35 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

      Both vaccine candidates induced robust immune responses across all antigens testedNo new safety signals were observed and both vaccine candidates were well tolerated consistent with past trialsNovavax continues to pursue partnering opportunities to advance further development of these programsGAITHERSBURG, Md., June 11, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial that showed both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid® and Fluzone HD, respective

      6/11/25 7:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Participate in Upcoming Investor Conferences

      GAITHERSBURG, Md., May 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside Chat Date: Wednesday, June 4, 2025 Time: 2:00 – 2:30 p.m. Eastern Time (ET) Location:            New York, NY Goldman Sachs 46th Annual Global Healthcare Conference: Presentation Date: Wednesday, June 11, 2025 Time: 2:00 – 2:35 p.m. ET Location: Miami Beach, FL A webcast of the fireside chat and presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcasts will be available for 30 days. About NovavaxNovavax, I

      5/29/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

      Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional COVID-19 vaccine milestones and ongoing tiered royalties to be recognized when earnedGAITHERSBURG, Md., May 19, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years

      5/19/25 7:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care